Warnings
Oxycodone; Paracetamol; Codeine; Caffeine; Morphine; Papaverine; Noscapine
偵測到 羥考酮, 乙醯氨酚, 可待因, 咖啡因, 嗎啡, 罌粟鹼, 諾斯卡品。 地點:瑞士。 日期:2025-12-19。 來源:drugchecking.ch。
Oxycodone; Paracetamol; Codeine; Caffeine; Morphine; Papaverine; Noscapine 藥丸 — 瑞士 — 2025-12-19
- Detected
- Oxycodone, Paracetamol, Codeine, Caffeine, Morphine, Papaverine, Noscapine
- Expected
- Unknown
- Logo
- Unknown
- Color
- Unknown
- Location
- Switzerland
- Date
- 2025-12-19
- Source
- drugchecking.ch
- Media
- 1 image
Detected Substances
- Oxycodone
- Paracetamol
- Codeine
- Caffeine
- Morphine
- Papaverine
- Noscapine
Expected vs Detected
No expected substance was recorded for this sample.
Detected result: Oxycodone, Paracetamol, Codeine, Caffeine, Morphine, Papaverine, Noscapine
Sample Details
No additional sample descriptors available.
Testing Context
- Location: 瑞士
- Date tested: 2025-12-19
- Source: drugchecking.ch
Harm Reduction
- Similar-looking pills can contain different substances or strengths.
- Use drug checking services when available.
- Start low and avoid assuming a logo identifies the contents.
SampleDNA Beta
3322 已連結的警告 · 了解常見雜質的相關資訊。
- Oxycodone檢測到
- Paracetamol檢測到
- Codeine檢測到
- Caffeine檢測到
- Morphine檢測到
- Papaverine檢測到
- Noscapine檢測到
相關樣本與組合
6-MAM + Acetylcodeine + Caffeine + Codeine + Diacetylmorphine + Morphine + Noscapine + Papaverine + Paracetamol + Unknown
3 份樣本
在相關藥物檢測結果中一起檢出的與此相關。
6-MAM + Acetylcodeine + Caffeine + Codeine + Diacetylmorphine + Morphine + Noscapine + Papaverine + Paracetamol
1 份樣本
在相關藥物檢測結果中一起檢出的與此相關。
6-MAM + Acetylcodeine + Caffeine + Codeine + Heroin + Morphine + Noscapine + Papaverine + Paracetamol
1 份樣本
在相關藥物檢測結果中一起檢出的與此相關。
Acetylcodeine + Caffeine + Codeine + Diacetylmorphine + Ketamine + Morphine + Noscapine + Papaverine + Paracetamol + Thebaine + Unknown
1 份樣本
在相關藥物檢測結果中一起檢出的與此相關。
6-MAM + Caffeine + Diacetylmorphine + Morphine + Noscapine + Papaverine + Paracetamol + Unknown
5 份樣本
在相關藥物檢測結果中一起檢出的與此相關。
SampleDNA 探索器
Links
This static page is intended as the readable export baseline for crawler and low-capability delivery.